Molecular pathology of lung cancer: key to personalized medicine.
about
Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosisLiquid biopsy in early stage lung cancerTumour biomarkers: homeostasis as a novel prognostic indicatorMolecular features in arsenic-induced lung tumorsP-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscapePulmonary monoclonal antibody delivery via a portable microfluidic nebulization platformDiscovering and understanding oncogenic gene fusions through data intensive computational approachesFluorescence in situ hybridization in surgical pathology: principles and applications.Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemA comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerDistinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung.Alveolar type II cells possess the capability of initiating lung tumor developmentMolecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancerClinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.Novel workflow for combining Raman spectroscopy and MALDI-MSI for tissue based studies.Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASMolecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.Personalized targeted therapy for lung cancerIdentification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.Drug Resistance to EGFR Inhibitors in Lung CancerTumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck.KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.Low-frequency KRAS mutations are prevalent in lung adenocarcinomasSuccess and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.Next-generation sequencing for lung cancer.Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma.Pingyangmycin and Bleomycin Share the Same Cytotoxicity Pathway.
P2860
Q23918758-96B28AF3-4337-4A79-83A1-B02FE9E32194Q28065994-D3826A8F-4CCD-4FF3-A5E7-B7DAF0F4E17AQ28069898-DFCA7ADB-F26D-4FFD-A7A5-A73165841F3AQ28396910-19DCF3CD-0691-4D01-84AE-1749D6C777DEQ28540825-75C9D63E-9EAB-4902-8D5E-F120CEF3C1E5Q30386192-605E767C-A342-4CD2-9A9E-C6796C3AC487Q31083417-5DF48782-C01E-40E2-9633-E9A97CB3CE9DQ33593910-E83B2E7E-D042-48E3-BF64-7B57AB9FF8F8Q33769117-94D76009-6092-42BF-A887-2D311C0F9F97Q34029261-EE0234E6-886C-4FF4-B2DF-66F5C0FEFD6CQ34295621-5C50F99F-E40B-44FD-9C96-773BAFAC988FQ34427314-E11527C4-85B5-47F9-AA15-0D5708FFE538Q34535276-B96EBC7B-FF45-491E-9F90-BF0113AB1C80Q35043965-E0BD2E34-4636-42A0-AF45-573F65478908Q35256540-37FED02A-7E67-4954-AD5B-600FC1124952Q35549714-2E9CFEB2-39A5-4D97-B654-932336F9CF3EQ35759003-B798C0E3-DB05-44C1-9B09-3A2B29DAD5E0Q35776848-FDCAA8C8-3C65-47DB-8B15-366CAE9228ABQ35843530-979A86C0-B027-4CC2-BD01-3130EADCE4ECQ36040606-9930B959-EBDA-488B-850A-CD27CF0C1B4DQ36063032-6CE01C29-36F1-45D5-8886-DFB6A30DC7D0Q36321826-D8965B17-B8A9-4504-BFB7-7CD9EA68A40EQ36331604-182DE768-D76A-4018-A0A3-A1AF42EF1F72Q36439363-1172E88A-F6BD-4747-98D7-1C53E4D98C89Q36662504-3AF74BEC-6723-4DB9-92B3-BE15C29B91AAQ36834883-AB3CC57A-5B58-4207-9289-9EE5EC9378DAQ37059865-A896259C-6E43-41B3-BF25-22D7A34E187EQ37067360-3CB17923-1CC8-4BE3-BAE3-5C5AC100B8AEQ37238413-567EDE23-C8A7-4200-B268-0E8D763FFA77Q37375834-11DD8BA0-26E0-4174-B692-C9EEEF09A39CQ37638241-D243DF42-E991-4502-A6C2-A2785872CAF4Q37703407-312452DF-EA0A-4150-B248-72A053263126Q38081987-5C1564A0-3F8D-4DA8-A3AC-32F48AE55C95Q38087239-BF69663F-8344-4119-9505-30F0847B337CQ38131798-7CE0F5AC-26A0-4058-91B6-2398B2029EF2Q38271717-FD96AAC1-8AD0-482B-9DF1-436E27BE3141Q38398139-3310A39F-BD45-450B-B0B8-0A5753D93CB3Q38658503-53ACAADD-75ED-4981-99B6-D94EE632A695Q38693861-07CC17FB-6AA6-4B1F-9C2A-7A67BE6E14B5Q38759996-F7E3C959-0745-43D5-BE80-F4346C6615A6
P2860
Molecular pathology of lung cancer: key to personalized medicine.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Molecular pathology of lung cancer: key to personalized medicine.
@ast
Molecular pathology of lung cancer: key to personalized medicine.
@en
Molecular pathology of lung cancer: key to personalized medicine.
@nl
type
label
Molecular pathology of lung cancer: key to personalized medicine.
@ast
Molecular pathology of lung cancer: key to personalized medicine.
@en
Molecular pathology of lung cancer: key to personalized medicine.
@nl
prefLabel
Molecular pathology of lung cancer: key to personalized medicine.
@ast
Molecular pathology of lung cancer: key to personalized medicine.
@en
Molecular pathology of lung cancer: key to personalized medicine.
@nl
P2093
P2860
P3181
P1433
P1476
Molecular pathology of lung cancer: key to personalized medicine.
@en
P2093
Alexander RE
Cummings OW
Davidson DD
Lopez-Beltran A
Maclennan GT
Montironi R
P2860
P2888
P304
P3181
P356
10.1038/MODPATHOL.2011.215
P577
2012-03-01T00:00:00Z
P5875
P6179
1016408971